Abstract
Background: Chronic prosthetic joint infection is a cause of patient morbidity and can be challenging to treat. Surgeons performing revision arthroplasty of the hip and knee are confronted with a growing number of patients with extensive loss of bone stock. The use of a modular endoprosthesis is a possible method of treatment in such patients.
Aim: The purpose of this study was to assess the functional outcomes and the success of a single and two stage revision procedure in eradicating chronic prosthetic joint infection using a femoral endoprosthesis.
Methods: A prospective database was reviewed of 20 patients who underwent a proximal, total or distal femoral endoprosthetic replacement after chronic prosthetic infection. Radiographs performed at the time of latest follow up were evaluated for signs of loosening, osteomyelitis and implant failure. The functional status was assessed using the Short Form (SF)-36 health survey score, Toronto extremity salvage score (TESS) and the Enneking score.
Results: Thirteen patients underwent a single stage revision procedure and seven had been treated with a staged revision. At the latest follow up none of the 13 patients treated with a single stage procedure had evidence of ongoing infection. Of the seven patients who had a staged revision, 3 patients had evidence of ongoing infection. The mean pre operative Enneking score for the entire group was 17.1 points and this improved to 47.5 points post operatively (p< 0.0002). The mean pre operative TESS score for the entire group was 42% and this improved to 59% post operatively (p< 0.005). There was also a statistically significant improvement in all of the components of the SF-36 score.
Conclusion: We believe that the use of a modular endo-prosthesis in the treatment of chronic prosthetic joint infection is a successful and viable option in eradicating infection, preserving the limb and providing a good functional result.
The abstracts were prepared by Mr Matt Costa and Mr Ben Ollivere. Correspondence should be addressed to Mr Costa at Clinical Sciences Research Institute, University of Warwick, Clifford Bridge Road, Coventry CV2 2DX, UK.
